Aarhus, Denmark (UroToday.com) Dr. Hyeoung Dong Yuk from Inje University Sanngye Paik Hospital in Seoul, South Korea presented data from a phase II trial investigating the efficacy of neoadjuvant atezolizumab in a patient population (cT2-4N0M0 prior to radical cystectomy (RC) for cystectomy-eligible patients), with endpoints of pathologic responses at the time of radical cystectomy.
Patients underwent molecular subtyping using the Basal/Squamous-Like (BASQ) classification and were divided into either luminal or basal types, for purposes of analysis. Patients received three cycles of atezolizumab prior to RC. Data was presented on the first 18 out of 40 patients. A pathologic complete response rate was seen in 5 of 18 patients (27.8%), with most of these responses observed in patients classified as basal (4/9, 44%) compared with luminal (1/7, 14.3%) subtype. Two patients discontinued therapy due to Grade 3 hepatitis. Additional maturation of the data is ongoing.
Abstract take-home message:
- Neoadjuvant atezolizumab for cT2-4 N0 M0 muscle-invasive bladder cancer was associated with a pathologic complete response rate of 28%, with most of these responses observed in patients of the basal subtype (preliminary/interim)
Presented by: Hyeong Dong Yuk, MD, Department of Urology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea, Department of Urology, Inje University Sanggye Paik Hospital, Seoul, South Korea
Written by: Dr. Vikram M. Narayan (@VikramNarayan), Urologic Oncology Fellow with Ashish M. Kamat, MD (@UroDocAsh), Professor, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX at the 17th meeting of the International Bladder Cancer Network, (IBCN, #IBCN2019) October 3rd – 5th, 2019 in Aarhus, Denmark.